Vol. 2 No. 5: Bortezomib (Velcade®) in multiple myeloma: an update

Articles

• Bortezomib: introduction

  Alessandro Corso

  https://doi.org/10.4081/hmr.v2i5.379

  Published: June 8, 2009

  267

  PDF: 225

  • PDF

• An update of the apex study

  Alessandro Corso

  https://doi.org/10.4081/hmr.v2i5.380

  Published: June 8, 2009

  288

  PDF: 1328

  • PDF

• Bortezomib-combination based therapy in relapsed-refractory myeloma patients

  Patrizia Zappasodi

  https://doi.org/10.4081/hmr.v2i5.381

  Published: June 8, 2009

  236

  PDF: 1371

  • PDF

• Bortezomib in newly diagnosed multiple myeloma patients

  Silvia Mangiacavalli

  https://doi.org/10.4081/hmr.v2i5.382

  Published: June 8, 2009

  183

  PDF: 308

  • PDF

• Frequency and characteristics of hematologic and non-hematologic Bortezomib-related toxicity

  Marzia Varettoni

  https://doi.org/10.4081/hmr.v2i5.383

  Published: June 8, 2009

  184

  PDF: 1658

  • PDF